NovaSight

The CureSight system [Image courtesy of NovaSight]NovaSight announced today that it is executing a large pivotal trial for its CureSight lazy eye digital treatment device.

Airport City, Israel-based NovaSight’s pivotal trial has the company on track to achieving FDA 510(k) approval for the CureSight device, according to a news release.

CureSight is an eye-tracking-based lazy eye treatment that NovaSight officials think could replace traditional eye patching. CureSight provides cloud monitoring to caregivers and physicians while the child watches their content of choice from the comfort of their own home.

The trial is the first of its kind in children against the gold standard patching treatment for lazy eye, the startup noted. It is recruiting 90 children with amblyopia aged four to nine and is taking place across six different medical centers in Israel, including Sheba Medical Center, where a previous trial observed visual and stereo acuity improveme…

The CureSight system [Image courtesy of NovaSight]

Israeli startup NovaSight announced today that it has raised $8 million in a Series A round meant to support a large multi-center randomized pivotal study of its lazy eye treatment device.

Study results will support potential FDA 510(k) clearance for the device.

The money will also support development of future eye care products such as eye-tracking based active glasses for myopia control.

NovaSight’s CureSight system is an eye-tracking based lazy eye treatment that NovaSight officials think could replace traditional eye patching. CureSight provides cloud monitoring to caregivers and physicians while the child watches their content of choice from the comfort of home.

NovaSight’s other flagship product is the EyeSwift system, a comprehensive portable vision assessment device that the company says accurately and objectively screens…